Featured Tickers:
Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Bausch + Lomb Corporation or Establishment Labs Holdings Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Bausch + Lomb Corporation and Establishment Labs Holdings Inc. compare based on key financial metrics to determine which better meets your investment needs.
About Bausch + Lomb Corporation and Establishment Labs Holdings Inc.
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgeries. The company offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides breast tissue expanders. The company sells products to physicians, hospitals, and clinics through distributors and its direct sales force in Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and North America. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
Latest Health Care Equipment & Supplies and Bausch + Lomb Corporation, Establishment Labs Holdings Inc. Stock News
As of November 24, 2025, Bausch + Lomb Corporation had a $5.5 billion market capitalization, compared to the Health Care Equipment & Supplies median of $292.1 million. Bausch + Lomb Corporation’s stock is down 11.9% in 2025, up 5.4% in the previous five trading days and down 20.28% in the past year.
Currently, Bausch + Lomb Corporation does not have a price-earnings ratio. Bausch + Lomb Corporation’s trailing 12-month revenue is $5.0 billion with a -6.1% net profit margin. Year-over-year quarterly sales growth most recently was 7.1%. Analysts expect adjusted earnings to reach $0.529 per share for the current fiscal year. Bausch + Lomb Corporation does not currently pay a dividend.
As of November 24, 2025, Establishment Labs Holdings Inc. had a $2.0 billion market cap, putting it in the 57th percentile of all stocks. Establishment Labs Holdings Inc.’s stock is up 52.3% in 2025, up 8.6% in the previous five trading days and up 65.37% in the past year.
Currently, Establishment Labs Holdings Inc. does not have a price-earnings ratio. Establishment Labs Holdings Inc.’s trailing 12-month revenue is $191.0 million with a -43.5% net profit margin. Year-over-year quarterly sales growth most recently was 33.8%. Analysts expect adjusted earnings to reach $-1.840 per share for the current fiscal year. Establishment Labs Holdings Inc. does not currently pay a dividend.
How We Compare Bausch + Lomb Corporation and Establishment Labs Holdings Inc. Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Bausch + Lomb Corporation and Establishment Labs Holdings Inc.’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions